• February 4, 2016
  • North America

Alder BioPharmaceuticals to Present at Leerink Partners 5th Annual Global Healthcare Conference

BOTHELL, WA. – Feb. 4, 2016 – Alder BioPharmaceuticals, Inc.,a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Cushing's disease, Congenital Adrenal Hyperplasia and autoimmune and inflammatory diseases, today announced that it will present at the Leerink Partners 5th Annual Global Healthcare Conference at 11:10 a.m. ET on Thursday, February 11, 2016 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.

A live audio webcast of the presentation can be accessed from the Investors section of the Alder website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.

Link: http://wsw.com/webcast/leerink26/aldr

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of Congenital Adrenal Hyperplasia or Cushing's disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies and an IND submission is planned for 2016. Additionally, Clazakizumab, is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab. For more information, please visit http://www.alderbio.com.

Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding the further development and potential commercialization of ALD403 and ALD1613, our expectations for the initiation of future clinical trials and studies, availability of clinical trial data, patient enrollment, the therapeutic potential of ALD403, ALD1613 and clazakizumab and the pursuit of strategic opportunities for clazakizumab. All forward-looking statements included in this press release are based on our management's beliefs and assumptions and on information currently available to our management, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this press release may turn out to be wrong and actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption "Risk Factors" set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, which was filed with the Securities and Exchange Commission (SEC) on November 5, 2015, and is available on the SEC's website at www.sec.gov. Additional information will also be set forth in our other reports and filings we will make with the SEC from time to time. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Media Contacts:
David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

Investor Relations Contact:
David Walsey
Alder Biopharmaceuticals
(425) 408-8032
[email protected]